Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain

NCT05561023 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT05561023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05561023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2022
Completion date
September 30, 2023
Enrollment
14 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hawthorn red combined refractory cancer pain